SynteractHCR, a full-service, international contract research organization (CRO), has hired Etienne Drouet as vice president, strategic development.
SAN DIEGO – Feb. 26, 2015 –SynteractHCR, a full-service, international contract research organization (CRO), has hired Etienne Drouet as vice president, strategic development. This is a new position created to augment the depth of the company’s oncology and complex trial expertise. Adding experience to an already capable senior management team brings new perspectives and enhances the team’s skills as this global CRO continues its focus on the small and mid-size biopharma segment.
Etienne Drouet has more than 20 years of experience in executive leadership, program and project management, clinical trial management, and research and development within the contract research and biopharmaceutical industries. At SynteractHCR he will join the senior management team, helping to develop company strategy and business models. His primary objective will be to ensure excellence in operational delivery to clients. He will report directly to CEO Wendel Barr.
“Since we work with smaller and mid-sized companies on complex global trials, integrating his extensive drug development knowledge is key to further improving both the strategic thinking and executional support our clients request,” said Wendel Barr, CEO of SynteractHCR. “We are delighted to have him on board the team.”
Mr. Drouet joins SynteractHCR from Premier Research where he was executive director, global oncology. Previously he was a program manager and senior project manager at ICON; held project management positions at AAI Pharma, and Cvitkovic and Associés Consultants; was a senior CRA at the Breast Cancer International Research Group; and a research scientist with Sanofi Aventis. Drouet has notable therapeutic experience in solid tumor and hematological cancers as well as CNS (central nervous systems).
He has an engineering degree in Biotechnology from the European School of Biotechnology in Strasbourg. Etienne Drouet also holds a Master in Science with a major in Cell Biology, Molecular Genetics, and Virology from the University Louis Pasteur in Strasbourg, Alsace, France.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.